Faculty Information - Ishii Rumi

（Last updated : 2024-08-26 14:05:44）

Ishii Rumi
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Department of Urology

Position Assistant Professor

■ Published papers

1.	Original article	Role of fractalkine-CX3CR1 axis in acute rejection of mouse heart allografts subjected to ischemia reperfusion injury 2022/02/01
2.	Other	Combination therapy of iNKT cell ligand and CD40-CD154 signal blockade establishes islet allograft acceptance in non-myeloablative bone marrow transplant recipients. 2019/05
3.	Original article	Evaluation of the impact of conventional immunosuppressant on the establishment of murine transplantation tolerance - an experimental study. 2019/04
4.	Other	Combination therapy of iNKT cell ligand and CD40-CD154 signal blockade establishes islet allograft acceptance in non-myeloablative bone marrow transplant recipients. 2019/01/31
5.	Other	In vitro α-galactosylceramide stimulation expands CD4+CD25+Foxp3- regulatory T cell precursors in murine thymocytes. 2018/03
6.	Original article	iNKT cell activation plus T-cell transfer establishes complete chimerism in a murine sublethal bone marrow transplant model. 2018/02
7.	Original article	Donor bone marrow cells are essential for iNKT cell-mediated Foxp3+ Treg cell expansion in a murine model of transplantation tolerance. 2017/04
8.	Original article	Transitional B cells predominantly reconstituted after a desensitization therapy using rituximab before kidney transplantation. 2017/04
9.	Case report	Donor with membranous nephropathy in preemptive, living-related kidney transplantation. 2016/12
10.	Original article	Clinical and pathological analyses of interstitial fibrosis and tubular atrophy cases after kidney transplantation. 2016/07
11.	Original article	Clonal deletion established via invariant NKT cell activation and costimulatory blockade requires in vivo expansion of regulatory T cells. 2016/02
12.	Original article	Clinical and pathological analyses of chronic vascular rejection after kidney transplantation. 2015/07
13.	Other	The phenotype of repopulating B cell after rituximab therapy in kidney transplant patients. 2014/11
Display 5 items
Display all(13)

■ Academic conference presentation

1.	CODEX multiplex immune-staining Identifies novel spatial indexes for antibody-mediated rejection diagnosis. 2023/04/20
2.	A novel method for ex vivo stimulation of mesenchymal stem cells via invariant natural killer T cell activation with ɑ-galactosylceramide. 2022/06/05
3.	Successful prophylaxis of antibody-mediated rejection by downregulation of C5 expression via RNA interference in a rat kidney transplant model. 2021/06/04
4.	A novel method for ex vivo treg expansion via human iNKT cell activation. 2019/06/04
5.	Fractalkine is crucial in ischemia reperfusion injury related to acute rejection in an allogeneic heart transplantation model. 2019/06/02
6.	Veto cell-transfer and iNKT cell activation establishes hematopoietic chimerism in non-myeloablative bone marrow transplant recipient. 2018/11/24
7.	In vitro α-galactosylceramide stimulation expands CD4⁺CD25⁺foxp3⁻ regulatory T cell precursors in murine thymocytes. 2018/06/02
8.	A novel method for iNKT cell-mediated ex vivo treg expansion applied to induce human transplant tolerance. 2017/05/01
9.	CD40/CD40 ligand signal controls cytotoxic ability of natural killer cells after invariant natural killer T cell stimulation. 2017/05/01
10.	Combination therapy of iNKT cell ligand and CD40-CD154 signal blockade establishes islet allograft tolerance in non-myeloablative bone marrow transplant recipients. 2017/05/01
11.	iNKT cell activation plus veto cell transfer yields complete chimerismin a murine sub-lethal bone marrow transplant model. 2017/04/29
12.	CD40/CD40 ligand signal controls cytotoxic ability of natural killer cells after invariant natural killer T cell stimulation. 2016/12/06
13.	Combination of veto cell transfer and NKT cell therapy helps establish complete hematopoietic chimerism in non-myeloablative BMT recipients. 2016/12/06
14.	Islet allografts survive permanently by inducing hematopoietic chimerism by activating invariant natural killer T cells under CD40-CD154 signal blockade. 2016/12/06
15.	Combination of veto cell transfer and iNKT cell therapy establishes complete hematopoietic chimerism in nonmyeloablative BMT recipients. 2016/08/20
16.	Combination of veto cell transfer and iNKT cell therapy establishes complete hematopoietic chimerism in non-myeloablative BMT recipients. 2016/06/14
17.	Contrasting effects of tacrolimus and everolimus on regulatory T cell activation and mixed hematopoietic chimerism induced by natural Killer T cell stimulation. 2016/06/14
18.	iNKT cell activation under co-stimulatory blockade establishes mixed chimerism through thymic regulatory T cell activation. 2016/06/12
19.	iNKT cell activation establishes transplant tolerance though the orchestration of regulatory and deletional mechanism. 2016/04/23
20.	Regulatory T cells expanded by activated iNKT cells facilitate migration of donor dendritic cells into the recipient thymus and subsequent establishment of clonal deletion. 2015/05/04
21.	The effect of rituximab therapy on regulatory B cell and prevention of chronic antibody mediated rejection in kidney transplantation recipients. 2015/05/04
22.	T cell transfer with iNKT cell activation facilitate engraftment of bone marrow cells without GvHD. 2015/05/03
23.	Donor specific tolerance can be induced by donor bone marrow transfer with activation of invariant naturel killer T cells. 2015/05/02
24.	Analysis of predictive and preventive factors for de novo DSA in Non-HLA sensitized kidney transplant recipients. 2014/07/29
25.	Changes in ABO-blood type antibody titers after single-dose rituximab administration. 2014/07/27
Display 5 items
Display all(25)

■ Education

Faculty of Medicine, Tokyo Women's Medical University, Graduated, doctor of medicine degree